Discover open access scientific publications

Search, annotate, share and cite publications

Publications by X. Wang

P2.15-30 Marital Status and Survival in Patients With Lung Cancer

Journal of Thoracic Oncology

English

P043 Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology

English

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

Journal of Thoracic Oncology

English

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study

Journal of Thoracic Oncology

English

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology

English

P1.13-24 EGFR-KDD Is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population

Journal of Thoracic Oncology

English

P1.16-61 Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Interim Analysis of Randomized Clinical Trial

Journal of Thoracic Oncology

English

P3.16-36 Adjuvant Chemotherapy May Improve the Outcome of Patients With Non-Small-Cell Lung Cancer With Metastasis of Intrapulmonary Lymph Nodes.

Journal of Thoracic Oncology

English

Hepatitis C Virus Re-Treatment in the Era of Direct-Acting Antivirals: Projections in the USA

Alimentary Pharmacology and Therapeutics

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by X. Wang

P2.15-30 Marital Status and Survival in Patients With Lung Cancer

P043 Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer

P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

P1.13-24 EGFR-KDD Is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population

P1.16-61 Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Interim Analysis of Randomized Clinical Trial

P3.16-36 Adjuvant Chemotherapy May Improve the Outcome of Patients With Non-Small-Cell Lung Cancer With Metastasis of Intrapulmonary Lymph Nodes.

Hepatitis C Virus Re-Treatment in the Era of Direct-Acting Antivirals: Projections in the USA